Breast cancer survivors have an increased risk of breast implant-associated ALCL, but the absolute risk is “extremely low,” according to researchers.
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Researchers have characterized treatment-related adverse events associated with antibody-drug conjugates in clinical trials.
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.
The new dosing option was approved based on data from a phase 2/3 trial.
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
The approval was based on data from the open-label phase 3 AHOD1331 trial.
Proteinuria was more frequent with regorafenib than with axitinib.
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Brentuximab vedotin improved event-free survival but not overall survival.
Patients with breast implants are at risk of developing squamous cell carcinoma and various types of lymphoma in the capsules around the implants.
Tucidinostat appears safe and effective in patients with relapsed/refractory peripheral T-cell lymphoma.
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.
Patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis have an increased risk of venous thromboembolism, a study suggests.
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
Exercise during chemotherapy may preserve cardiorespiratory fitness, a study suggests.
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.